Celltrion Acquires Eli Lilly's NJ Facility for $330M

Celltrion's US subsidiary acquired Imclone Systems, a facility in New Jersey from Eli Lilly for $330M. The move is part of a strategic plan to protect Celltrion's biologic production capacity. The acquisition will enable Celltrion to expand its capabilities in the US market and strengthen its position in the biologics manufacturing industry.

Celltrion's US subsidiary has acquired Imclone Systems, a facility in New Jersey from Eli Lilly for $330 million. The acquisition is part of Celltrion's strategic plan to protect its biologic production capacity and expand its capabilities in the US market. The move aims to strengthen Celltrion's position in the biologics manufacturing industry and mitigate potential tariff risks.

The acquisition includes a 391,000 square-foot facility in Branchburg, New Jersey, which will be used to produce both Celltrion's and Eli Lilly's products. Celltrion expects to receive regulatory approval for the plant this year, with production of both companies' products expected to begin by the end of 2026. The deal is part of Celltrion's long-term strategy to invest $1 billion in operations, facility growth, and future expansion Celltrion to Acquire Eli Lilly's $330M Production Plant^[1].

The acquisition comes at a time when the US is considering new pharma tariffs that could impact the industry. Celltrion has already taken steps to mitigate these risks, including stockpiling two years' worth of inventory within the United States and expanding local contracts with CMOs. The company also plans to purchase a large-scale cGMP manufacturing plant in the US to further reduce tariff exposure South Korea's Celltrion pays $330m for Eli Lilly factory in US^[2].

Celltrion's chairman, Seo Jung-jin, has stated that the acquisition will eliminate all future tariff-related risks for the company's pharmaceutical products. The company expects to close the transaction by the end of this year, pending regulatory approvals Celltrion to buy Eli Lilly’s production facility to avoid US tariffs^[3].